RXRXRecursion Pharmaceuticals, Inc.
Nov 4, 2026 — Q3 2026 Earnings Release
Chart by TradingViewThe schedule
- Wed4Nov
- Tue9Feb
- Wed5May
- Wed4Aug
Resolved
- Wed5Aug
MIXED · $3.22 at outcome
Recursion Pharmaceuticals missed Q2 earnings estimates but provided positive updates on its partnership with Genentech, advancing a neuroscience target into early discovery. The company also lowered its 2026 cash operating expense guidance, which supported the stock's rise despite the earnings miss.
Recursion Pharmaceuticals reports Q2 2026 financial results and provides operational updates.
- Fri27Feb
BEAR · $3.54 at outcome
Price reached or fell below bear floor ($3.20) at outcome date.
